Cardioprotection by farnesol: Role of the mevalonate pathway

Cardiovascular Drugs and Therapy

Volumn 27, Issue 4, 2013, Pages 269-277

  Szucs, Gergo ^a   Murlasits, Zsolt ^b,c   Török, Szilvia ^a   Kocsis, Gabriella F ^a   Pálóczi, János ^a   Görbe, Anikó ^a   Csont, Tamás ^a,c   Csonka, Csaba ^a,c   Ferdinandy, Péter ^c,d  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF MEMPHIS   (United States)

^c PHARMAHUNGARY GROUP   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Farnesol; Ischemia reperfusion; Mevalonate pathway; Peroxynitrite; Protein geranylgeranylation

Indexed keywords

3 NITROTYROSINE; CHOLESTEROL; DOLICHOL; FARNESOL; MEVALONIC ACID; UBIDECARENONE; UBIQUINONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISOLATED HEART; MALE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PRENYLATION; RAT; REPERFUSION; REPERFUSION INJURY; WISTAR RAT;

ANIMALS; ANIMALS, NEWBORN; CARDIOTONIC AGENTS; CELL SURVIVAL; CELLS, CULTURED; CHOLESTEROL; DOLICHOL; FARNESOL; MALE; MEVALONIC ACID; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; MYOCYTES, CARDIAC; PROTEIN PRENYLATION; RATS; RATS, WISTAR; TYROSINE; UBIQUINONE;

EID: 84880262305     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-013-6460-2     Document Type: Article

References (38)

1. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev. 2007;59:418-58.
2. Ferdinandy P, Csonka C, Csont T, Szilvassy Z, Dux L. Rapid pacing-induced preconditioning is recaptured by farnesol treatment in hearts of cholesterol-fed rats: role of polyprenyl derivatives and nitric oxide. Mol Cell Biochem. 1998;186:27-34.
3. Qamar W, Sultana S. Farnesol ameliorates massive inflammation, oxidative stress and lung injury induced by intratracheal instillation of cigarette smoke extract in rats: an initial step in lung chemoprevention. Chem Biol Interact. 2008;176:79-87.
4. Jahangir T, Khan TH, Prasad L, Sultana S. Farnesol prevents Fe-NTA-mediated renal oxidative stress and early tumour promotion markers in rats. Hum Exp Toxicol. 2006;25:235-42.
5. Khan R, Sultana S. Farnesol attenuates 1,2-dimethylhydrazine induced oxidative stress, inflammation and apoptotic responses in the colon of Wistar rats. Chem Biol Interact. 2011;192:193-200.
6. Crick DC, Andres DA, Waechter CJ. Farnesol is utilized for protein isoprenylation and the biosynthesis of cholesterol in mammalian cells. Biochem Biophys Res Commun. 1995;211:590-9.
7. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-30.
8. Resh MD. Trafficking and signaling by fatty-acylated and prenylated proteins. Nat Chem Biol. 2006;2:584-90.
9. Leung KF, Baron R, Seabra MC. Thematic review series: lipid posttranslational modifications. geranylgeranylation of Rab GTPases. J Lipid Res. 2006;47:467-75.
10. Reddy S, Comai L. Lamin A, farnesylation and aging. Exp Cell Res. 2012;318:1-7.
11. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-9.
12. Aberg F, Appelkvist EL, Dallner G, Ernster L. Distribution and redox state of ubiquinones in rat and human tissues. Arch Biochem Biophys. 1992;295:230-4.
13. Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol. 1990;30:596-608.
14. 2+overload during postischemic reperfusion. Am J Physiol. 1994;266:2174-81.
15. Doucey MA, Hess D, Cacan R, Hofsteenge J. Protein C-mannosylation is enzyme-catalysed and uses dolichyl-phosphate-mannose as a precursor. Mol Biol Cell. 1998;9:291-300.
16. Takeda J, Kinoshita T. GPI-anchor biosynthesis. Trends Biochem Sci. 1995;20:367-71.
17. Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem. 1985;54:631-64.
18. Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol. 2003;138:532-43.
19. Yasmin W, Strynadka KD, Schulz R. Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res. 1997;33:422-32.
20. Kocsis GF, Pipis J, Fekete V, et al. Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts. Am J Physiol Heart Circ Physiol. 2008;294:2406-9.
21. Csonka C, Kupai K, Kocsis GF, et al. Measurement of myocardial infarct size in preclinical studies. J Pharmacol Toxicol Methods. 2010;61:163-70.
22. Epstein WW, Lever D, Leining LM, Bruenger E, Rilling HC. Quantitation of prenylcysteines by a selective cleavage reaction. Proc Natl Acad Sci U S A. 1991;88:9668-70.
23. Rousseau G, Varin F. Determination of ubiquinone-9 and 10 levels in rat tissues and blood by high-performance liquid chromatography with ultraviolet detection. J Chromatogr Sci. 1998;36:247-52.
24. Dini B, Dolfi C, Santucci V, et al. Effects of ageing and increased haemolysis on the levels of dolichol in rat spleen. Exp Gerontol. 2001;37:99-105.
25. Csont T, Gorbe A, Bereczki E, et al. Biglycan protects cardiomyocytes against hypoxia/reoxygenation injury: role of nitric oxide. J Mol Cell Cardiol. 2010;48:649-52.
26. Li X, Heinzel FR, Boengler K, Schulz R, Heusch G. Role of connexin 43 in ischemic preconditioning does not involve intercellular communication through gap junctions. J Mol Cell Cardiol. 2004;36:161-3.
27. Bentinger M, Grunler J, Peterson E, Swiezewska E, Dallner G. Phosphorylation of farnesol in rat liver microsomes: properties of farnesol kinase and farnesyl phosphate kinase. Arch Biochem Biophys. 1998;353:191-8.
28. Ali BR, Nouvel I, Leung KF, Hume AN, Seabra MC. A novel statin-mediated "prenylation block-and-release" assay provides insight into the membrane targeting mechanisms of small GTPases. Biochem Biophys Res Commun. 2010;397:34-41.
29. Lane KT, Beese LS. Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. J Lipid Res. 2006;47:681-99.
30. Brar BK, Jonassen AK, Egorina EM, et al. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology. 2004;145:24-35.
31. Xiang SY, Vanhoutte D, Del Re DP, et al. RhoA protects the mouse heart against ischemia/reperfusion injury. J Clin Invest. 2011;121:3269-76.
32. Dougherty CJ, Kubasiak LA, Frazier DP, et al. Mitochondrial signals initiate the activation of c-Jun N-terminal kinase (JNK) by hypoxia- reoxygenation. FASEB J. 2004;18:1060-70.
33. Matejikova J, Kucharska J, Pancza D, Ravingerova T. The effect of antioxidant treatment and NOS inhibition on the incidence of ischemia-induced arrhythmias in the diabetic rat heart. Physiol Res. 2008;57 Suppl 2:55-60.
34. Molyneux SL, Florkowski CM, Richards AM, Lever M, Young JM, George PM. Coenzyme Q10; an adjunctive therapy for congestive heart failure? N Z Med J. 2009;122:74-9.
35. Kapusta L, Zucker N, Frenckel G et al. From discrete dilated cardiomyopathy to successful cardiac transplantation in congenital disorders of glycosylation due to dolichol kinase deficiency (DK1-CDG). Heart Fail Rev. 2012;18:187-96
36. Lefeber DJ, de Brouwer AP, Morava E, et al. Autosomal recessive dilated cardiomyopathy due to DOLK mutations results from abnormal dystroglycan O-mannosylation. PLoS Genet. 2011;7:e1002427.
37. Chagas CE, Vieira A, Ong TP, Moreno FS. Farnesol inhibits cell proliferation and induces apoptosis after partial hepatectomy in rats. Acta Cir Bras. 2009;24:377-82.
38. Joo JH, Liao G, Collins JB, Grissom SF, Jetten AM. Farnesol-induced apoptosis in human lung carcinoma cells is coupled to the endoplasmic reticulum stress response. Cancer Res. 2007;67:7929-36.